Guggenheim upgraded GRAIL Inc. (NASDAQ: GRAL) from Neutral to Buy with a $100 price target, saying recent clinical data had strengthened its conviction in the company’s leading position in multi-cancer early detection (MCED) testing. Shares surged more than 3% in intra-day trading Wednesday.
The firm acknowledged ongoing criticism of GRAIL’s Galleri test but said it remained the most advanced commercial MCED product, supported by extensive prospective data. Analysts argued that while Galleri was not flawless, it offered a clear competitive edge and substantial total addressable market potential.
Guggenheim’s upgrade reflected several key factors: increased confidence following positive PATHFINDER 2 ESMO data, evolving feedback from key opinion leaders, fresh proprietary analysis indicating a large U.S. and U.K. market opportunity, and recently secured partnerships to access that market.
The firm said uncertainties remained regarding Medicare reimbursement and regulatory approvals for MCEDs but emphasized that GRAIL’s early lead and strong clinical foundation positioned it to capture significant long-term growth.
